146 related articles for article (PubMed ID: 32212814)
21. Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study.
Reesink-Peters N; Hougardy BM; van den Heuvel FA; Ten Hoor KA; Hollema H; Boezen HM; de Vries EG; de Jong S; van der Zee AG
Gynecol Oncol; 2005 Mar; 96(3):705-13. PubMed ID: 15721415
[TBL] [Abstract][Full Text] [Related]
22. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.
Zhang B; Sun T; Xue L; Han X; Zhang B; Lu N; Shi Y; Tan W; Zhou Y; Zhao D; Zhang X; Guo Y; Lin D
Carcinogenesis; 2007 May; 28(5):1067-73. PubMed ID: 17183065
[TBL] [Abstract][Full Text] [Related]
23. Reversed CD4/CD8 ratios of tumor-infiltrating lymphocytes are correlated with the progression of human cervical carcinoma.
Sheu BC; Hsu SM; Ho HN; Lin RH; Torng PL; Huang SC
Cancer; 1999 Oct; 86(8):1537-43. PubMed ID: 10526283
[TBL] [Abstract][Full Text] [Related]
24. Intratumoral T cell subset ratios and Fas ligand expression on brain tumor endothelium.
Yu JS; Lee PK; Ehtesham M; Samoto K; Black KL; Wheeler CJ
J Neurooncol; 2003; 64(1-2):55-61. PubMed ID: 12952286
[TBL] [Abstract][Full Text] [Related]
25. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma.
Koyama S; Koike N; Adachi S
J Cancer Res Clin Oncol; 2001 Jan; 127(1):20-6. PubMed ID: 11206267
[TBL] [Abstract][Full Text] [Related]
26. The "Fas counterattack" is not an active mode of tumor immune evasion in colorectal cancer with high-level microsatellite instability.
Houston AM; Michael-Robinson JM; Walsh MD; Cummings MC; Ryan AE; Lincoln D; Pandeya N; Jass JR; Radford-Smith GL; O'Connell J
Hum Pathol; 2008 Feb; 39(2):243-50. PubMed ID: 17961631
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system.
Zhu Q; Liu JY; Xu HW; Yang CM; Zhang AZ; Cui Y; Wang HB
World J Gastroenterol; 2005 Oct; 11(39):6125-9. PubMed ID: 16273638
[TBL] [Abstract][Full Text] [Related]
28. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
29. Fas ligand expression in cervical adenocarcinoma: relevance to lymph node metastasis and tumor progression.
Kase H; Aoki Y; Tanaka K
Gynecol Oncol; 2003 Jul; 90(1):70-4. PubMed ID: 12821344
[TBL] [Abstract][Full Text] [Related]
30. Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Kolberg-Liedtke C; Gluz O; Heinisch F; Feuerhake F; Kreipe H; Clemens M; Nuding B; Malter W; Reimer T; Wuerstlein R; Graeser M; Shak S; Nitz U; Kates R; Christgen M; Harbeck N
Breast Cancer Res; 2020 May; 22(1):47. PubMed ID: 32408905
[TBL] [Abstract][Full Text] [Related]
31. Treatment outcomes of patients with adenocarcinoma of the uterine cervix after definitive radiotherapy and the prognostic impact of tumor-infiltrating CD8+ lymphocytes in pre-treatment biopsy specimens: a multi-institutional retrospective study.
Miyasaka Y; Yoshimoto Y; Murata K; Noda SE; Ando K; Ebara T; Okonogi N; Kaminuma T; Yamada S; Ikota H; Yokoo H; Ohno T; Nakano T
J Radiat Res; 2020 Mar; 61(2):275-284. PubMed ID: 32052042
[TBL] [Abstract][Full Text] [Related]
32. FasL expression in colorectal carcinoma and its significance in immune escape of cancer.
Tong Q; Liu K; Wang G
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(1):79-81. PubMed ID: 16711013
[TBL] [Abstract][Full Text] [Related]
33. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
34. Digitally quantified CD8+ cells: the best candidate marker for an immune cell score in non-small cell lung cancer?
Kilvaer TK; Paulsen EE; Andersen S; Rakaee M; Bremnes RM; Busund LR; Donnem T
Carcinogenesis; 2020 Dec; 41(12):1671-1681. PubMed ID: 33035322
[TBL] [Abstract][Full Text] [Related]
35. Altered expression of survivin, Fas and FasL contributed to cervical cancer development and metastasis.
Wu SF; Zhang JW; Qian WY; Yang YB; Liu Y; Dong Y; Zhang ZB; Zhu YP; Feng YJ
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(15):2044-50. PubMed ID: 23280017
[TBL] [Abstract][Full Text] [Related]
36. CD8-positive Tumor-infiltrating Lymphocytes and Prognosis in Radiotherapy for Uterine Cervical Squamous Cell Carcinoma.
Miyasaka Y; Yoshimoto Y; Ando K; Murata K; Irie D; Sato H; Noda SE; Ikota H; Nakano T; Yokoo H; Ohno T
Anticancer Res; 2023 May; 43(5):2077-2084. PubMed ID: 37097697
[TBL] [Abstract][Full Text] [Related]
37. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
Tian JQ; Wang ZP; Rodriguez R; Fu JS; Lu JZ; Ma BL
Urology; 2006 May; 67(5):1093-8. PubMed ID: 16635513
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.
Feng W; Li Y; Shen L; Cai XW; Zhu ZF; Chang JH; Xiang JQ; Zhang YW; Chen HQ; Fu XL
Oncotarget; 2016 Feb; 7(6):7227-40. PubMed ID: 26811495
[TBL] [Abstract][Full Text] [Related]
39. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
[TBL] [Abstract][Full Text] [Related]
40. Expression of FasL in squamous cell carcinomas of the cervix and cervical intraepithelial neoplasia and its role in tumor escape mechanism.
Ibrahim R; Frederickson H; Parr A; Ward Y; Moncur J; Khleif SN
Cancer; 2006 Mar; 106(5):1065-77. PubMed ID: 16456813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
